The ongoing COVID 19 epidemic has brought to the fore many concerns related to use of immunosuppressive agents (ISAs) in dermatology. While it is unclear whether the patients on ISAs for skin conditions are more prone to develop COVID 19, and what impact the ISA may have on the clinical outcome if a patient does get infected, rationalizations based on the specific immune effects of each drug, and existing literature on incidence of various infections with each, are possible. In this review, we provide the readers with practically useful insights into these aspects, related to the conventional ISAs, and briefly mention the clinical outcome data available on related scenarios from other patient groups so far. In the end, we have attempted to provide some clinically useful points regarding practical use of each dermatologically relevant conventional ISA in the current scenario. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; azathioprine; ciclosporine; cyclophosphamide; dermatology; immunology; immunosuppressive; methotrexate; mycophenolate; pathogenesis; steroids.
This article is protected by copyright. All rights reserved.
Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.Dermatol Ther. 2020 May 27:e13686. doi: 10.1111/dth.13686. Online ahead of print. Dermatol Ther. 2020. PMID: 32458530
Systemic immunosuppressive therapy for inflammatory skin diseases in children: Expert consensus-based guidance for clinical decision-making during the COVID-19 pandemic.Pediatr Dermatol. 2020 Apr 22. doi: 10.1111/pde.14202. Online ahead of print. Pediatr Dermatol. 2020. PMID: 32320494 Review.
Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?Dermatol Ther. 2020 May 5:e13509. doi: 10.1111/dth.13509. Online ahead of print. Dermatol Ther. 2020. PMID: 32367558
ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.Drugs R D. 2007;8(2):103-12. doi: 10.2165/00126839-200708020-00005. Drugs R D. 2007. PMID: 17324008 Review.
Noncutaneous considerations of COVID-19 for dermatology practices.J Cosmet Dermatol. 2020 Apr 16. doi: 10.1111/jocd.13444. Online ahead of print. J Cosmet Dermatol. 2020. PMID: 32298514